Contrasting Immunome (NASDAQ:IMNM) & Bicara Therapeutics (NASDAQ:BCAX)

Bicara Therapeutics (NASDAQ:BCAX) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Bicara Therapeutics and Immunome, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	0	0	6	1	3.14
Immunome	0	0	7	0	3.00

Bicara Therapeutics currently has a consensus target price of $43.00, suggesting a potential upside of 199.03%. Immunome has a consensus target price of $28.83, suggesting a potential upside of 172.01%. Given Bicara Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Bicara Therapeutics is more favorable than Immunome.

Profitability

This table compares Bicara Therapeutics and Immunome’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	N/A	N/A
Immunome	-3,014.59%	-48.63%	-41.62%

Valuation and Earnings

This table compares Bicara Therapeutics and Immunome”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
Immunome	$10.13 million	65.32	-$106.81 million	($8.11)	-1.31

Bicara Therapeutics has higher earnings, but lower revenue than Immunome.

Insider and Institutional Ownership

44.6% of Immunome shares are held by institutional investors. 8.6% of Immunome shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Bicara Therapeutics beats Immunome on 6 of the 10 factors compared between the two stocks.

About Bicara Therapeutics

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

About Immunome

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.